Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFRopen access
- Authors
- Kim, Seongjae; Park, Jung Min; Park, Soeun; Jung, Eunsun; Ko, Dongmi; Park, Minsu; Seo, Juyeon; Nam, Kee Dal; Kang, Yong Koo; Lee, Kyoungmin; Farrand, Lee; Kim, Yoon-Jae; Kim, Ji Young; Seo, Jae Hong
- Issue Date
- Nov-2023
- Publisher
- BMC
- Keywords
- Doxazosin; Triple-negative breast cancer; c-MET; EGFR; Drug accessibility; Metastasis; Cancer stem cells
- Citation
- Journal of Experimental & Clinical Cancer Research, v.42, no.1
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Experimental & Clinical Cancer Research
- Volume
- 42
- Number
- 1
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64692
- DOI
- 10.1186/s13046-023-02866-z
- ISSN
- 1756-9966
1756-9966
- Abstract
- BackgroundTriple-negative breast cancer (TNBC) is characterized by aggressive growth and a high propensity for recurrence and metastasis. Simultaneous overexpression of c-MET and EGFR in TNBC is associated with worse clinicopathological features and unfavorable outcomes. Although the development of new c-MET inhibitors and the emergence of 3rd-generation EGFR inhibitors represent promising treatment options, the high costs involved limit the accessibility of these drugs. In the present study, we sought to investigate the therapeutic potential of doxazosin (DOXA), a generic drug for benign prostate hyperplasia, in targeting TNBC.MethodsThe effect of DOXA on TNBC cell lines in vitro was evaluated in terms of cell viability, apoptosis, c-MET/EGFR signaling pathway, molecular docking studies and impact on cancer stem cell (CSC)-like properties. An in vivo metastatic model with CSCs was used to evaluate the efficacy of DOXA.ResultsDOXA exhibits notable anti-proliferative effects on TNBC cells by inducing apoptosis via caspase activation. Molecular docking studies revealed the direct interaction of DOXA with the tyrosine kinase domains of c-MET and EGFR. Consequently, DOXA disrupts important survival pathways including AKT, MEK/ERK, and JAK/STAT3, while suppressing CSC-like characteristics including CD44high/CD24low subpopulations, aldehyde dehydrogenase 1 (ALDH1) activity and formation of mammospheres. DOXA administration was found to suppress tumor growth, intra- and peri-tumoral angiogenesis and distant metastasis in an orthotopic allograft model with CSC-enriched populations. Furthermore, no toxic effects of DOXA were observed in hepatic or renal function.ConclusionsOur findings highlight the potential of DOXA as a therapeutic option for metastatic TNBC, warranting further investigation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 4. Research institute > Cancer Institute > 1. Journal Articles
- 3. Graduate School > Graduate School > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.